NCT06765161View on ClinicalTrials.gov

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

PHASE3RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

February 6, 2025

Primary Completion Date

January 6, 2027

Study Completion Date

January 6, 2027

Conditions

Myasthaenia Gravis

Interventions

DRUG

efgartigimod administration

efgartigimod infusion

Trial Locations (1)

J8Y1W2

RECRUITING

Clinique Neuro-Outaouais, Gatineau

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

argenx

INDUSTRY

lead

Clinique Neuro-Outaouais

OTHER